Therapeutic co-administration of TGF-β-blocking and anti-PD-L1 antibodies inhibit TGF-β signaling in CAFs, facilitated T cell penetration into the tumor nest, and, therefore, provoke effective anti-tumor immunity and tumor regression [135, 136]. This evidence concerns the gene CD274 and neoplasm.